NDC 49643-352 Canyon Ragweed Pollen

Product Information

What is NDC 49643-352?

The NDC code 49643-352 is assigned by the FDA to the product Canyon Ragweed Pollen which is product labeled by Allermed Laboratories, Inc.. The product's dosage form is and is administered via form. The product is distributed in 4 packages with assigned NDC codes 49643-352-05 5 ml in 1 vial, multi-dose , 49643-352-10 10 ml in 1 vial, multi-dose , 49643-352-30 30 ml in 1 vial, multi-dose , 49643-352-50 50 ml in 1 vial, multi-dose . This page includes all the important details about this product, including active and inactive ingredients, pharmagologic classes, product uses and characteristics, UNII information, RxNorm crosswalk and the complete product label.

NDC Product Code49643-352
Proprietary Name What is the Proprietary Name?
The proprietary name also known as the trade name is the name of the product chosen by the medication labeler for marketing purposes.
Canyon Ragweed Pollen
Product Labeler Information What is the Labeler Name?
Name of Company corresponding to the labeler code segment of the Product NDC.
Allermed Laboratories, Inc.
Labeler Code49643
Start Marketing Date What is the Start Marketing Date?
This is the date that the labeler indicates was the start of its marketing of the drug product.
03-12-1974
Listing Expiration Date What is the Listing Expiration Date?
This is the date when the listing record will expire if not updated or certified by the product labeler.
12-31-2022
Exclude Flag What is the NDC Exclude Flag?
This field indicates whether the product has been removed/excluded from the NDC Directory for failure to respond to FDA"s requests for correction to deficient or non-compliant submissions ("Y"), or because the listing certification is expired ("E"), or because the listing data was inactivated by FDA ("I"). Values = "Y", "N", "E", or "I".
U
NDC Code Structure

What are the uses for Canyon Ragweed Pollen?


Product Packages

NDC Code 49643-352-05

Package Description: 5 mL in 1 VIAL, MULTI-DOSE

NDC Code 49643-352-10

Package Description: 10 mL in 1 VIAL, MULTI-DOSE

NDC Code 49643-352-30

Package Description: 30 mL in 1 VIAL, MULTI-DOSE

NDC Code 49643-352-50

Package Description: 50 mL in 1 VIAL, MULTI-DOSE

This product is EXCLUDED from the official NDC directory .

Product Details

Canyon Ragweed Pollen Active Ingredients UNII Codes

  • ALNUS RHOMBIFOLIA POLLEN (UNII: 7X8HL8GRTM)
  • ALNUS RHOMBIFOLIA POLLEN (UNII: 7X8HL8GRTM) (Active Moiety)
  • MEDICAGO SATIVA POLLEN (UNII: G515RAI9FY)
  • MEDICAGO SATIVA POLLEN (UNII: G515RAI9FY) (Active Moiety)
  • SUAEDA NIGRA POLLEN (UNII: FZU040QDS7)
  • SUAEDA NIGRA POLLEN (UNII: FZU040QDS7) (Active Moiety)
  • ALTERNARIA ALTERNATA (UNII: 52B29REC7H)
  • ALTERNARIA ALTERNATA (UNII: 52B29REC7H) (Active Moiety)
  • ULMUS AMERICANA POLLEN (UNII: 89BAT511BD)
  • ULMUS AMERICANA POLLEN (UNII: 89BAT511BD) (Active Moiety)
  • FRAXINUS VELUTINA POLLEN (UNII: LJT6I6Z8FD)
  • FRAXINUS VELUTINA POLLEN (UNII: LJT6I6Z8FD) (Active Moiety)
  • SALIX LASIOLEPIS POLLEN (UNII: 808UWJ59FI)
  • SALIX LASIOLEPIS POLLEN (UNII: 808UWJ59FI) (Active Moiety)
  • POPULUS TREMULOIDES POLLEN (UNII: 928OC2TJDA)
  • POPULUS TREMULOIDES POLLEN (UNII: 928OC2TJDA) (Active Moiety)
  • ASPERGILLUS FUMIGATUS (UNII: X88DF51T48)
  • ASPERGILLUS FUMIGATUS (UNII: X88DF51T48) (Active Moiety)
  • CASUARINA EQUISETIFOLIA POLLEN (UNII: OZJ4OE173N)
  • CASUARINA EQUISETIFOLIA POLLEN (UNII: OZJ4OE173N) (Active Moiety)
  • PASPALUM NOTATUM POLLEN (UNII: V003SHB7VK)
  • PASPALUM NOTATUM POLLEN (UNII: V003SHB7VK) (Active Moiety)
  • BASSIA HYSSOPIFOLIA POLLEN (UNII: 35487N1IC9)
  • BASSIA HYSSOPIFOLIA POLLEN (UNII: 35487N1IC9) (Active Moiety)
  • FAGUS GRANDIFOLIA POLLEN (UNII: 34X886W1H4)
  • FAGUS GRANDIFOLIA POLLEN (UNII: 34X886W1H4) (Active Moiety)
  • POPULUS TRICHOCARPA POLLEN (UNII: H8QYU50Z2D)
  • POPULUS TRICHOCARPA POLLEN (UNII: H8QYU50Z2D) (Active Moiety)
  • QUERCUS VELUTINA POLLEN (UNII: 294L626TT0)
  • QUERCUS VELUTINA POLLEN (UNII: 294L626TT0) (Active Moiety)
  • JUGLANS NIGRA POLLEN (UNII: 1BV28146ZR)
  • JUGLANS NIGRA POLLEN (UNII: 1BV28146ZR) (Active Moiety)
  • SALIX NIGRA POLLEN (UNII: 6M2JIH93ZN)
  • SALIX NIGRA POLLEN (UNII: 6M2JIH93ZN) (Active Moiety)
  • BOTRYTIS CINEREA (UNII: TBW53313S7)
  • BOTRYTIS CINEREA (UNII: TBW53313S7) (Active Moiety)
  • CALLISTEMON CITRINUS POLLEN (UNII: 62OII98F1T)
  • CALLISTEMON CITRINUS POLLEN (UNII: 62OII98F1T) (Active Moiety)
  • ACER NEGUNDO POLLEN (UNII: P6K070AR8V)
  • ACER NEGUNDO POLLEN (UNII: P6K070AR8V) (Active Moiety)
  • BASSIA SCOPARIA POLLEN (UNII: 07A108ZKW5)
  • BASSIA SCOPARIA POLLEN (UNII: 07A108ZKW5) (Active Moiety)
  • AMBROSIA SALSOLA POLLEN (UNII: 662J7FTA7T)
  • AMBROSIA SALSOLA POLLEN (UNII: 662J7FTA7T) (Active Moiety)
  • CYCLACHAENA XANTHIFOLIA POLLEN (UNII: V80TPZ0T6J)
  • CYCLACHAENA XANTHIFOLIA POLLEN (UNII: V80TPZ0T6J) (Active Moiety)
  • JUGLANS CALIFORNICA POLLEN (UNII: 2147EPR64I)
  • JUGLANS CALIFORNICA POLLEN (UNII: 2147EPR64I) (Active Moiety)
  • JUNIPERUS CALIFORNICA POLLEN (UNII: 0H1V4V5V9L)
  • JUNIPERUS CALIFORNICA POLLEN (UNII: 0H1V4V5V9L) (Active Moiety)
  • QUERCUS DUMOSA POLLEN (UNII: P5W45RU6E4)
  • QUERCUS DUMOSA POLLEN (UNII: P5W45RU6E4) (Active Moiety)
  • PHALARIS ARUNDINACEA POLLEN (UNII: FAY1Y90VJ9)
  • PHALARIS ARUNDINACEA POLLEN (UNII: FAY1Y90VJ9) (Active Moiety)
  • CANDIDA ALBICANS (UNII: 4D7G21HDBC)
  • CANDIDA ALBICANS (UNII: 4D7G21HDBC) (Active Moiety)
  • AMBROSIA AMBROSIOIDES POLLEN (UNII: 81214Y871U)
  • AMBROSIA AMBROSIOIDES POLLEN (UNII: 81214Y871U) (Active Moiety)

NDC to RxNorm Crosswalk

What is RxNorm? RxNorm is a normalized naming system for generic and branded drugs that assigns unique concept identifier(s) known as RxCUIs to NDC products.The NDC to RxNorm Crosswalk for this produdct indicates multiple concept unique identifiers (RXCUIs) are associated with this product:
  • RxCUI: 1011991 - Trichothecium roseum allergenic extract 100 MG/mL Injectable Solution
  • RxCUI: 1011991 - Trichothecium roseum allergenic extract 100 MG/ML Injectable Solution
  • RxCUI: 1011991 - Trichothecium roseum extract 0.1 GM/ML Injectable Solution
  • RxCUI: 1011991 - Trichothecium roseum extract 100 MG/ML Injectable Solution
  • RxCUI: 1115265 - bluegum eucalyptus pollen extract 50 MG/ML Injectable Solution

Canyon Ragweed Pollen Inactive Ingredients UNII Codes

The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product.

* Please review the disclaimer below.

Canyon Ragweed Pollen Product Label

FDA filings in the form of structured product labels are documents that include all published material associated whith this product. Product label information includes data like indications and usage generic names, contraindications, active ingredients, strength dosage, routes of administration, appearance, usage, warnings, inactive ingredients, etc.

Product Label Table of Contents



Warnings



This allergenic product is intended for use by physicians who are experienced in the administration of allergenic extracts, and the emergency care of anaphylaxis, or for use under the guidance of an allergy specialist.
This allergenic extract is not directly interchangeable with other allergenic extracts. The initial dose must be based on skin testing as described in the dosage and administration section of this insert. Patients being switched from other types of extracts, such as alum precipitated extracts, should be started as though they were coming under treatment for the first time. Patients should be instructed to recognize adverse reaction symptoms and cautioned to contact the physician's office if reaction symptoms occur. As with all allergenic extracts, severe systemic reactions may occur. In certain individuals these systemic reactions may occur. In certain individuals these reactions may be life threatening. Patients should be observed for at least 20 minutes following treatment, and emergency measures as well as personnel trained in their use should be immediately available in the event of a life threatening reaction.
This product should not be injected intravenously (see Dosage and Administration). Refer also to the Warnings, Precautions, Adverse Reactions and Overdosage sections below.

The only approved method for determining hypersensitivity to Allermed Laboratories Allergenic Extracts is by diagnostic skin testing (See DOSAGE AND ADMINISTRATION — DIAGNOSIS).
Physicians who administer allergenic extract should have emergency medication and equipment available to treat anaphylaxis 14. See Precautions, Adverse Reactions and Overdosage below.
To reduce the risk of anaphylaxis, the following measures must be observed:

  • Concentrated extract must be diluted before use for intradermal skin testing and for beginning immunotherapy. It should never be injected intravenously during testing or treatment procedures.
  • Patients who are highly sensitive, determined from clinical findings and test results, may require that treatment start with a very weak concentration of extract, such as 1:10,000,000 v/v.
  • The dosage of fresh (new) extract given to a patient receiving maintenance injections must be reduced to one-fourth the amount given from the previous (old) lot (See Immunotherapy, last paragraph).
  • Patients who are transferred to standardized extract after previous treatment with unstandardized extract must be skin tested with serial dilutions, starting with a 1:100,000 v/v dilution of the standardized extract, to determine a safe, non-reacting starting dose.
  • Patients who are transferred to this extract after treatment with alum precipitated or other modified extract must re-start injections with the beginning recommended dose of this extract.

Description



Allergenic extract contains the aqueous extractables from allergenic source material in extracting solution containing 0.25% sodium chloride, 0.125% sodium bicarbonate, and 50% glycerol. 0.4% phenol is added as a preservative. The weight by volume value shown on the label is a measurement of extract concentration, rather than extract potency. Extracts for which U.S. standards exist are labeled in allergy units, in addition to w/v strength.


Clinical Pharmacology



Positive skin tests with allergenic extract are the result of histamine release from mast cells sensitized with allergen specific IgE. The exact mechanisms by which immunotherapy relieves symptoms of allergy are still under investigation. Elevations in allergen-specific IgG antibodies and an increase in the activity of T suppressor lymphocytes appear to be some of the immunologic changes that occur from hyposensitization. 1,2,3


Indications And Usage



Allergenic extract may be used as a diagnostic skin test reagent in persons suspected of being sensitive to the allergenic source material from which the extract is made. Skin tests should be used in conjunction with a thorough allergic history to establish the relevance of a given allergen in the etiology of allergic disease. 4,5,6
Immunotherapy with allergenic extract is indicated in persons suffering from allergic rhinitis, bronchitis, conjunctivitis, urticaria and asthma. The therapeutic efficacy of allergenic extract has been proven in ragweed, grass, and mountain cedar pollinosis, cat-induced asthma and hypersensitivity to hymenoptera venoms. 7-12
Immunotherapy may be used along with or exclusive of antihistamines and other medications used to control allergic symptoms.


Contraindications



Allergenic extract should not be administered to a non-allergic person. However, there are no absolute contraindications to the use of allergenic extract for treatment in appropriate individuals. Relative contraindications include: EXTREME SENSITIVITY TO AN ALLERGEN - Determined from the allergic history, or from previous anaphylaxis following skin testing or subcutaneous injection; AUTOIMMUNE DISEASE - Individuals with autoimmune disease may be at risk, due to the possibility of routine immunizations exacerbating symptoms of the underlying disease; PREGNANCY - In limited controlled studies of women receiving allergenic extract during conception and throughout all trimesters of pregnancy, no evidence was found that extract is harmful to the fetus or mother. However, because of the known pharmacologic action of histamine on uterine muscle, any treatment that might result in the release of significant amounts of this mediator should be avoided if possible 13. See Precaution #4; MYOCARDIAL INFARCTION - Patients who have experienced a recent myocardial infarction may not be able to tolerate immunotherapy. As in all of the above circumstances, the benefit to risk ration must be carefully evaluated; BLEEDING DIATHESIS - Patients with a bleeding tendency should not be tested or treated with allergenic extract, unless the physician responsible believes that such procedures are safe to perform.
Allergenic extract should be temporarily withheld from patients if any of the following conditions exist: (1) severe symptoms of hay fever and/or asthma; (2) infection or flu accompanied by fever; and (3) exposure to excessive amounts of clinically relevant allergens prior to skin testing or immunotherapy.


Precautions



  • Extract should be stored at 2°C to 8°C since higher temperatures may adversely affect the stability of the product. Do not freeze.
  • After the needle is inserted subcutaneously, the plunger should be withdrawn slightly to check for the presence of blood in the syringe. If blood is observed, a new injection should be prepared and given at another site, observing the same precautions.
  • Treatment with beta-blocking drugs may make patients refractory to the usual dose of epinephrine, in the event epinephrine is required to control an adverse allergic reaction.
  • PREGNANCY CATEGORY C. Allergenic extract. Animal reproduction studies have not been conducted with allergenic extract. It is also not known whether allergenic extract can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Allergenic extract should be given to a pregnant woman only if clearly needed.
  • PATIENT INSTRUCTIONS: Patients should be instructed to remain in the physician's office for at least 20 minutes after skin testing and after each treatment injection, and immediately notify the physician if symptoms of a generalized reaction or shock occur.
  • CARCINOGENESIS, MUTAGENESIS, IMPAIRMENT OF FERTILITY: Long term studies have not been conducted with allergenic extracts to determine their potential for carcinogenesis, mutagenesis, and impairment of fertility.
  • LACTATION: Data are not available on the secretion of allergenic extract in human milk and it is not known what affect this might have on the nursing infant.
  • PEDIATRIC USE: The dose of allergenic extract recommended for children is the same as that used for adults, except in the injection of large doses of extract for treatment. In this case, the amount of extract given to a child may be modified so that the discomfort of the injection is minimized.

Adverse Reactions



Local Reactions: The occurrence of a hive 5 to 15 minutes after the subcutaneous injection of extract does not require a reduction in dosage. However, a local reaction with edema larger than 2 cm in diameter or swelling and redness that persist for several hours or longer indicates that too much extract has been given. Treatment should be altered as follows:

  • Additional injections should not be given until all evidence of the reaction has disappeared.
  • The next injection administered should be 50% of the last non-reacting dose or less, depending upon the size and severity of the local reaction.
  • Subsequent injections should be continued at the reduced dosage unless the physician responsible for treatment believes that it is safe to increase the dose, and that possible clinical improvement would result form the administration of a larger dose of extract.

  • Systemic Reactions:Systemic (generalized) reactions may range from a mild exacerbation of the patient's allergic symptoms to hives, anaphylactic shock, or even death from anaphylaxis. The reaction usually occurs 5 to 20 minutes after injection. As a rule, the more quickly a reaction develops, the more serious it is likely to become. Symptoms may include sneezing, coughing, itching, shortness of breath, abdominal cramps, vomiting, diarrhea, tachycardia, hypotension and respiratory failure in severe cases. The reaction is usually stopped by the subcutaneous injection of Epinephrine HCL 1:1,000 (See Overdosage below). The oral administration of antihistamines and the placement of a tourniquet proximal to the injection site are helpful adjuncts. In the event that additional measures are required, it may be necessary to treat the patient for BRONCHOSPASM with intravenous aminophylline, intravenous fluids and corticosteroids; for HYPOTENSION with vasopressors, volume repletion, isoproterenol and corticosteroids; for LARYNGEAL OBSTRUCTION with oxygen and tracheostomy and for CARDIAC ARREST with cardiopulmonary resuscitation and other appropriate measures.
    Immunotherapy after anaphylaxis should be continued if the cause of the reaction can be identified and appropriate precautions taken to insure that a subsequent reaction does not occur.


Overdosage



A strong local reaction to the injection of extract may be treated with oral antihistamines and the local application of a cold compress. The dosage must be reduced and additional extract must not be given until all evidence of the reaction has disappeared.
A systemic reaction following the injection of extract must be treated immediately. Reported procedures include (Ref. #4, vol. 2, p. 888):

  • 0.01 mL/kg up to 0.2 mL of aqueous epinephrine HCL 1:1000 subcutaneously at the injection site of antigen.
  • 0.01 mL/kg up to 0.3 mL of aqueous epinephrine HCL 1:1000 subcutaneously at another site.
  • Diphenhydramine intravenously or intramuscularly, 1.25 mg/kg up to 50 mg.
  • Tourniquet above the injection site of antigen.
  • Specific reactions:

    • Brochospasm: intravenous aminophylline 4 mg/kg up to 500 mg given over 10 to 15 minutes, aqueous hydrocortisone 5 mg/kg up to 200 mg, oxygen.
    • Laryngeal edema: oxygen, intubation, tracheostomy.
    • Hypotension: vasopressors, fluids, corticosteroids.
    • Cardiac arrest: resuscitation, sodium bicarbonate, defibrillation, antiarrhythmia medications.

Dosage And Administration



Diagnosis: Concentrated extract may be used for scratch or prick testing providing the patient is not extremely sensitive. In this case, the extract should be diluted 10 fold before a scratch or prick test is performed. Extract for intradermal testing must be used as follows:

a. Patients with a negative scratch or prick test: Patients who do not react who do not react to a valid scratch or prick test should be tested intradermally with 0.05 mL of a 1:1000 v/v dilution of the concentrate. If the test is negative, a second test should be performed with 0.05 mL of a 1:100 v/v dilution or concentrate.
b. Patients with positive scratch or prick tests: It is not advisable to perform an intradermal skin test if the patient has a positive scratch or prick test.
c. Patients tested only by the intradermal method: Patients suspected of being highly allergic should be tested with 0.05 mL of a 1:100,000 v/v dilution of the concentrate. A negative test should be followed by repeat tests using 10 fold stronger concentrations until the maximum dose of 0.05 mL of a 1:100 v/v dilution is reached.

Interpretation of Results
Scratch and Prick Test
A negative test shows only a slight red area at the site of scarification or prick penetration. Positive tests are scored as follows:

1+ Erythema with 5 mm wheal
2+ Erythema with a 5-10 mm wheal
3+ Erythema with a 10-15 mm wheal
4+ Erythema with a wheal 15 mm (or larger) with pseudopodia

Intradermal Test
A negative test shows no change in the appearance and size of the 5 mm wheal created by the I.D. injection of 0.05 mL of extract. Positive tests are scored as follows:

1+ Erythema 10-20 mm with a 5-10 mm wheal
2+ Erythema 20-30 mm with a 5-10 mm wheal
3+ Erythema 30-40 mm with a 10-15 mm wheal
4+ Erythema greater than 40 mm with a 15 mm wheal (or larger) with pseudopodia

Immunotherapy

Allergenic extract should be administered subcutaneously in the outer aspect of the upper arm using a sterile tuberculin syringe and needle. The skin should be cleaned with 70% alcohol and aseptic technique should be observed in removing the extract from the vial. Care must be taken to avoid injecting the extract into a blood vessel because of the risk of anaphylaxis.
Concentrated extract must be diluted before administration to new patients. A 1:100,000 v/v dilution of concentrate is usually satisfactory to start treatment. However, as a precaution against overdose, a skin test with the intended starting dose should be done to help evaluate the patient's sensitivity to the product. If the skin response is larger than 5 mm edema/15 mm erythema, the extract is too strong and must be diluted before it is given subcutaneously. The doses shown in the Dosage Schedule (Table 1) below are recommended unless the patient's skin test response and allergic history indicates that more dilute extract should be used.
Little is known about the required accumulated dosage of allergen that is needed to relieve symptoms. However, studies have shown that high dose immunotherapy is efficacious in the treatment of allergic rhinitis and asthma. For this reason, treatment with extract from Vial #5 is recommended, providing the patient can tolerate the extract without experiencing local or systemic reactions. Treatment with Vial #6 may be used for patients who have not had adverse reactions to extract in Vial #5 and who require more concentrated extract to control or relieve symptoms.
Patients who have received allergenic extract for maintenance therapy SHOULD NOT be given the same dose from a fresh vial of extract. IT IS ADVISABLE TO REDUCE THE DOSAGE OF FRESH EXTRACT TO ONE-FOURTH THE AMOUNT GIVEN FROM A PREVIOUS LOT OF EXTRACT MADE AT THE SAME CONCENTRATION AND BY THE SAME FORMULA.

Table 1 - Suggested Dosage Schedule
No.
Vial #1
1:100,000 w/v
frequency twice
weekly
mL
Vial #2
1:10,000 w/v
frequency twice
weekly
mL
Vial #3
1:1,000 w/v
frequency once
weekly
mL
Vial #4
1:100 w/v
frequency once
weekly
mL
Vial #5
1:10 w/v
frequency every
two-four weeks
mL
Vial #6
Concentrate
frequency every
two-four weeks
mL
1
0.025
0.025
0.025
0.025
0.025
0.025
2
0.05
0.050.050.050.050.05
3
0.10
0.10
0.10
0.10
0.10
0.10
4
0.15
0.15
0.15
0.15
0.15
0.15
5
0.20
0.20
0.20
0.20
0.20
0.20
6
0.25
0.25
0.25
0.25
0.25
0.25
7
0.30
0.30
0.30
0.30
0.30
0.30

Supplied



Allergenic extract is supplied in dropper vials for scratch or prick testing and in 10, 30, and 50 mL vials for bulk use.

WARRANTY

Allermed Laboratories, Inc. certifies that allergenic extract prepared within the Laboratories meets the safety and sterility standards of the F.D.A. Because the Laboratories have no control over the conditions under which extract is sued, or the purposes intended, neither a good nor a bad effect following its administration is warranted.
The users of this product should be aware of the potential dangers involved in the injection of allergenic extract and accept the risk of any consequences resulting from such injections.
No representatives of the Laboratories may change this warranty whether written, oral or implied. The buyer or user must assume full responsibility for the product after it leaves the premises of the Laboratories.


References



  • Levy, D.A., L.M., Lichtenstein, E.O. Goldstein and K. Ishizaka. Immunologic and cellular changes accompanying the therapy of pollen allergy. J. Clinical Investigations. 50:360, 1971.
  • Evans, R., H. Pence, H. Kaplan and R. Rocklin. The effect of immunotherapy on humoral and cellular response in ragweed hayfever. J. Clinical Investigations. 57:1378, 1976.
  • Ishizaka, K. Cellular events in the IgE antibody response. Adv. In Immunology. 23:50, 1976.
  • Middleton, Elliott, Jr., C.E. Reed and E.F. Ellis (Eds.) Allergy, Principles and Practice Vols. 1&2, C.V. Mosby 1978.
  • Sheldon, J.M., R.G. Lovell and K.P. Matthews. A Manual of Clinical Allergy. W.B. Saunders, 1967.
  • Nelson, H.S. Diagnostic procedures in allergy. I. Allergy skin testing. Ann. Allergy. 51:411, 1983.
  • Norma, P.S., W.L. Winkenwerder and L.M. Lichtenstein. Immunotherapy of hay fever with ragweed antigen E: comparisons with whole pollen extract and placebos. J. Allergy. 42:93, 1968.
  • Milner, F.H. and E.C. Tees. Specific sensitivity to individual grass pollens in some hay fever patients. Clinical Allergy. 2:83, 1972.
  • Frankland, A.W. and R. Augustine. Grass pollen antigens effective in treatment. Clinical Science. 23:95, 1962.
  • Pence, H.L., D.Q. Mitchell, R.L. Greely, B.R. Updegraff and H.A. Selfridge. Immunotherapy for mountain cedar pollinosis: a double-blind controlled study. J. Allergy ad Clinical Immunology. 58:39, 1976.
  • Taylor, W.W., J.L. Ohman, Jr. and F.C. Lowell. Immunotherapy in cat-induced asthma. Double-blind trial with evaluation of bronchial responses to cat allergen and histamine. J. Allergy and Clinical Immunology. 61:283. 1978.
  • Lichtenstein, L.M., M.D. Valentine and A.K. Sobotka. Insect allergies. The state of the art. J. Allergy and Clinical Immunology. 61:268, 1978.
  • Metzger, W.J., E. Turner and R. Patterson. The safety of immunotherapy during pregnancy. J. Allergy and Clinical Immunology. 61:268. 1978.
  • Ouellette, J.J. Emergency management of allergic reactions. Modern Medicine 99, 1975.

* Please review the disclaimer below.